Solvonis Therapeutics' experimental drug SVN-015, targeting cocaine and methamphetamine addiction, has passed initial safety screening by the US National Institute on Drug Abuse. The agency will fund further studies, including mouse tests to assess the drug's effects and safety, without cost to Solvonis. SVN-015 aims to affect brain transporters for dopamine and serotonin, potentially offering a new treatment where none currently exist. The drug is still in early discovery stages, years from human trials, but the agency's support validates its potential.
Japanese software firm Micware, through its subsidiary Micware Navigations, has partnered with Wiz Ltd. to offer cloud and AI security solutions leveraging Wiz's platform. This initiative addresses growing security complexities in AI and cloud enviro...
Pandora announced that CFO Anders Boyer will retire on November 30, 2026, after over 14 years with the company. Paulo Garcia, with 25 years of international experience in consumer goods and former CFO of Walmart Mexico & Central America, will join Pa...
RENK Group AG reported a record €1.2 billion in orders for the first half of 2026, a 29.7% increase from the previous year, driven by strong demand in defense. The company achieved its highest-ever quarterly order intake of €612.8 million in Q2, with...
RENK Group AG reported a record order intake of around €1.2 billion in the first half of 2026, a 29.7% increase from the previous year, driven by strong demand in defense. Revenue rose slightly by 2.7% to €637.2 million, while adjusted EBIT grew by 1...
Italy's biggest bank has significantly increased its investment in Ether ETFs by tripling its holdings, signaling a strong bet on the cryptocurrency's potential growth. At the same time, the bank has reduced its stake in IBIT shares, indicating a str...
